Currently Viewing:
American Society of Hematology Annual Meeting & Exposition
Research to Look Out for at ASH 2018
November 26, 2018
Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings
December 01, 2018
Studies at ASH Evaluate Episodic ED Utilization, Adherence, QOL in Sickle Cell Disease
December 01, 2018
Dr Theresa Keegan: AYAs Continue to Be Underrepresented in Clinical Trials
December 01, 2018
Dr Elizabeth Griffiths: Mutational Data Help Inform Clinical Prognosis, Treatment Protocol in AML
December 01, 2018
Length of Hospital Stay Key Driver of Costs Associated With CRS Following CAR T Treatment
December 02, 2018
Dr Jeff Sharman Discusses Standard of Care for CLL Based on Treatment Setting
December 03, 2018
Dr Alison Moskowitz on the Importance of Patients Understanding Their Diagnosis, Treatment Options
December 03, 2018
Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL
December 03, 2018
ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection
December 03, 2018
iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL
December 03, 2018
Currently Reading
Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome
December 03, 2018
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 18, 2018
Dr Jeff Sharman: Cost of Therapy Is a Major Challenge in CLL
January 06, 2019
Dr Theresa Keegan on Barriers, Facilitators to Clinical Trial Participation Among AYAs
January 07, 2019
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
January 08, 2019
Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple Myeloma
January 10, 2019
Dr Robert Rifkin on Lack of Education Surrounding Biosimilars
January 22, 2019

Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome

Patients with Down syndrome are at an increased risk for developing leukemia, but how much of an increased risk depends on age, explained Irene Roberts, MD, professor of pediatric hematology, MRC molecular hematology unit and pediatrics, MRC Weatherall Institute of Molecular Medicine.


Patients with Down syndrome are at an increased risk for developing leukemia, but how much of an increased risk depends on age, explained Irene Roberts, MD, professor of pediatric hematology, MRC molecular hematology unit and pediatrics, MRC Weatherall Institute of Molecular Medicine.

Transcript

How at risk are patients with Down syndrome for developing leukemia compared with the general population?

That very much depends on the age. So, for example, in a lifetime, say up to age 60, there’s about a 12-fold increased risk of acute myeloid leukemia compared to individuals without Down syndrome and a 13-fold increase of acute lymphoblastic leukemia. But if you’re a young child, the statistics are a lot different. So, the risk of a myeloid leukemia in children under 4, for example, climbs to 114-fold compared to other young children who don’t have Down syndrome.

What’s the reason behind this risk?

That’s a very good question, and we don’t fully know the answer, and a lot of people are researching on that. The assumption is that it has something to do with the extra chromosome in the blood cells. So, having an extra chromosome, 21, in some way, affects the behavior of the blood cell, which makes it more likely to transform. But which genes do it, we still don’t know.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!